*Aurinia Pharmaceuticals Inc.

Changing the course of autoimmune disease

Inspired by patients. Driven to make an impact.

Aurinia’s Response to COVID-19

View

Latest News

April 8, 2021 • 6:05am EDT

Aurinia Presents Data Demonstrating LUPKYNIS™ (voclosporin) Efficacy Across Lupus Nephritis Biopsy Classes at National Kidney Foundation 2021 Spring Clinical Meetings

Read Press Release View All News

March 15, 2021 • 6:05am EDT

Aurinia Announces Positive Cost-Effectiveness Assessment of LUPKYNIS™ (voclosporin) in Latest ICER Draft Evidence Report

Read Press Release View All News

March 2, 2021 • 6:05am EST

Aurinia Pharmaceuticals to Present at Three Upcoming March Investor Conferences

Read Press Release View All News